Labriola Leanne T, Sadda Srinivas R
Medical Retina Service, Doheny Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles, CA 90033, USA.
Semin Ophthalmol. 2011 Nov;26(6):387-91. doi: 10.3109/08820538.2011.622339.
To report improvement in cystoid macular edema from central retinal vein occlusion with one injection of ranibizumab after failure with seven injections of bevacizumab.
Case report.
A 74-year-old female developed persistent blurred vision for three months. Ocular examination revealed macular edema secondary to nonischemic central retinal vein occlusion. The patient was treated with intravitreal bevacizumab (1.25 mg in 0.05 mL). She received seven injections (every 5-6 weeks). Vision fluctuated between 20/30 and 20/60 with minimal variation in central foveal thickness (449-574 μm). However, weeks after one injection of ranibizumab the patient's vision improved to 20/20 with near resolution of macular edema (CFT = 343 μm).
Patients with no response to bevacizumab injections can show a rapid and large improvement with ranibizumab. This underscores the important differences between these two medications. Further study is required to determine if these initial effects of ranibizumab can be maintained.
报告一名视网膜中央静脉阻塞所致黄斑囊样水肿患者，在接受七次贝伐单抗注射治疗失败后，单次注射雷珠单抗病情得到改善的情况。
病例报告。
一名74岁女性出现持续视力模糊三个月。眼部检查发现非缺血性视网膜中央静脉阻塞继发黄斑水肿。患者接受玻璃体内注射贝伐单抗（0.05 mL中含1.25 mg）治疗。她接受了七次注射（每5 - 6周一次）。视力在20/30至20/60之间波动，中心凹厚度变化极小（449 - 574μm）。然而，在单次注射雷珠单抗数周后，患者视力提高到20/20，黄斑水肿几乎消退（中心凹厚度 = 343μm）。
对贝伐单抗注射无反应的患者使用雷珠单抗可迅速且显著改善病情。这突出了这两种药物之间的重要差异。需要进一步研究以确定雷珠单抗的这些初始疗效能否维持。
